The words and actions of US President Donald Trump are rocking the pharmaceutical industry. On May 5, he said he…
REGULATORY
Novartis’ Fabhalta, UCB’s Briviact and More to Join NHI Price List on Aug. 15
The Central Social Insurance Medical Council (Chuikyo) on August 7 approved 12 medicines for reimbursement listing later this month, with the largest peak sales projected for Novartis Pharma’s Fabhalta (iptacopan), a treatment for paroxysmal nocturnal hemoglobinuria (PNH). Fabhalta is expected…
To read the full story
Related Article
- Haihe Steps into Japan Oncology Space as CEO Sees Growth Potential
January 10, 2025
- Pfizer’s Antibiotic Zavicefta Now Available in Japan
November 13, 2024
- Haihe’s MET Inhibitor Haiyitan Set for Launch on Oct. 11
September 25, 2024
- UCB’s Anti-Epileptic Drug Briviact Now Available in Japan
September 2, 2024
- Takeda Rolls Out CMV Drug Livtencity in Japan
August 29, 2024
- GSK Introduces Asthma Drug Relvar for Children in Japan
August 26, 2024
- Lilly’s BTK Inhibitor Jaypirca Hits Japan Market for MCL
August 22, 2024
- Fabhalta, Omjjara, Avigan Now Available in Japan
August 19, 2024
REGULATORY
- Pfizer’s UC Drug, MSD’s PAH Therapy, and More Up for Panel Review on June 4
May 22, 2025
- MHLW Orders Label Revisions for Diuretics, Zolgensma
May 22, 2025
- LDP Generic League Calls for Necessary Pricing Steps to Ensure Quality and Supply
May 22, 2025
- MHLW Working Group Begins Discussions to Update List of “Stable Supply Medicines”
May 22, 2025
- OTC-Like Drug Is Hardest Topic in Tripartite Social Security Talks: Japan PM
May 22, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…